Posted by Michael Wonder on 30 Sep 2024
Fresenius Kabi and Formycon receive US FDA approval for biosimilar Otulfi (ustekinumab-aauz)
30 September 2024 - In accordance with the patent settlement between Fresenius Kabi, Formycon and Johnson & Johnson, Fresenius Kabi has the right to market Otulfi in the US no later than 22 February 2025.
Fresenius Kabi and Formycon announced today that the US FDA has approved Otulfi™ (ustekinumab-aauz), its ustekinumab biosimilar referencing Stelara (ustekinumab).
